课题基金 / 基金详情

Rapid pre-release sterility test for PET Drugs.

Rapid pre-release sterility test for PET Drugs.
PET 药物的快速发布前无菌测试。
批准号:
10258453
负责人:
Arkadij Elizarov
金额:
$16.81万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-20 至 2023-08-31

项目摘要

项目成果

Arkadij Elizarov的其他基金

相似基金

相关文献

中文摘要
翻译
摘要
英文摘要
Abstract Traditional process of sterility testing requires a 14-day sample incubation in different media. That makes it impossible to establish a pre-release sterility testing for PET tracers, which have half-lives of 9 to 110 minutes and must be released within 1 hour after synthesis. Moreover, even with numerous controls in place, in the past two years two of three of the largest US PET tracer manufacturers have been issued sterility warnings from the FDA. Trace-Ability proposes a novel approach to rapid sterility testing without incubation, with sterility results available within 1 hour. The solution will take advantage of microfluidic chip technology and will be completely automated and incorporated into the only commercially available and validated automated PET tracer QC platform. Proposed rapid sterility test involves assessing viability by probing whether cellular membranes are intact, and whether there is DNA in those membranes. This will be achieved by selective fluorescent staining of up to 250 µL of sample on a microfluidic chip. To check cell viability, we will take advantage of two stains. The difference of the two signals will indicate whether the organism may be able to reproduce. Proposed solution is intended to enable automated sterility testing and include it into pre-release automated QC workflows for the 1st time in history of PET. Specific Aim 1: Selection of fluorescent stains that can provide the high selectivity and differentiability of viable cells. A combination of stains will be selected that can differentiate between viable and non-viable organisms for 10 typical bacterial species. Evaluation criteria: (1) Viability stains incorporate within 30 minutes, (2) Organisms retain viability after staining, (3) Stains for nonviable organisms have twice the binding affinity of the viability stains, being able to displace any free DNA. (4) bound:unbound ratio > 1000. (5) Limits of Detection down to 10 CFU (colony-forming unit). Specific Aim 2: Development of microfluidic analysis chip for Signal to Noise (S/N) ratio optimization. Taking the optimal stains established in aim 1, these will then be mixed with bacteria in low concentration and loaded onto microfluidic chips with varying channel sizes and shapes while monitoring fluorescence emission for background reduction and S/N increase. Evaluation criteria: (1) a limit of detection (LOD) of 1 CFU, (2) a 100-fold improvement in S/N, (3) filling times less than 30 minutes for 250 μL. Once feasibility is verified in Phase 1, this work has a clear path to commercialization by implementing the test into the Tracer-QC platform. This will allow PET manufactures to have a complete QC package in a single automated system that meets all compliance criteria. This work can extend well beyond PET to compounding pharmacies and other small-scale manufacturers, offering simplification of the experimental setup, procedural changes in production, and regulatory changes to improve patient safety.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Establishing industrial production of components that enable expanding accessibility of PET imaging to cancer patient population.
  • 批准号:
    10698218
  • 项目类别:
  • 资助金额:
    $15.62万
  • 财政年份:
    2023
  • 负责人:
    Arkadij Elizarov
  • 依托单位:
Broad Implementation of a universal solution for quality control modernization in PET radio-pharmaceutical manufacturing industry.
  • 批准号:
    10452538
  • 项目类别:
  • 资助金额:
    $100.0万
  • 财政年份:
    2020
  • 负责人:
    Arkadij Elizarov
  • 依托单位:
Broad Implementation of a universal solution for quality control modernization in PET radio-pharmaceutical manufacturing industry.
  • 批准号:
    10675471
  • 项目类别:
  • 资助金额:
    $100.0万
  • 财政年份:
    2020
  • 负责人:
    Arkadij Elizarov
  • 依托单位:
国内基金
海外基金
肺癌CPSF3通过调控BCLAF1 pre-mRNA APA抑制NK细胞免疫监视的作
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    孟勐
  • 依托单位:
α-Klotho通过SIRT7去乙酰化U3-55k调控pre-rRNA的加工在衰老BMSCs成骨分化中的作用研究
口腔疾病综合防治和关键技术研究-基于牙周多组学多模态的 伴Pre-DM牙周炎预警模型构建
  • 批准号:
    2025C02103
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    孙伟莲
  • 依托单位:
皮肤黑素瘤中 circROR1调控FOXO4 pre-mRNA可变 剪切促进肿瘤转移的机制研究
  • 批准号:
    2024JJ5541
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    谢慧清
  • 依托单位: